Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Recent trials questioned the benefit of platelet function testing, while new data linked low reactivity to bleeding, supporting a therapeutic window concept.
Does personalized antiplatelet therapy based on platelet function testing improve ischemic and bleeding outcomes in patients undergoing percutaneous coronary intervention?
Key Points
- To review evidence linking on-treatment platelet reactivity to ischemic and bleeding outcomes and establish consensus cutoff values for personalized antiplatelet therapy.
- An expert working group evaluated clinical trial and observational evidence examining the relationship between platelet function tests and clinical outcomes after percutaneous coronary intervention.
- The panel assessed high and low on-treatment platelet reactivity to adenosine diphosphate across standard testing platforms to define a therapeutic window.
- High on-treatment platelet reactivity to adenosine diphosphate remains a strong prognostic risk factor for post-percutaneous coronary intervention ischemic events, particularly stent thrombosis.
- Low on-treatment platelet reactivity to adenosine diphosphate is associated with an elevated risk of clinical bleeding complications.
- Recent randomized controlled trials testing treatment modification based on platelet function testing failed to demonstrate clinical benefit, though significant methodological limitations were identified.
Structured PICO
Does personalized antiplatelet therapy based on platelet function testing improve ischemic and bleeding outcomes in patients undergoing percutaneous coronary intervention?
P
Population
Patients treated with percutaneous coronary intervention receiving dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker
I
Intervention
Platelet function testing to guide P2Y12 receptor inhibitor therapy (personalized antiplatelet therapy)
C
Comparator
Standard antiplatelet therapy without platelet function testing
O
Outcome
Thrombotic events (ischemia, stent thrombosis) and bleeding events
This consensus document proposes updated cutoff values for high and low on-treatment platelet reactivity to ADP to define a therapeutic window for P2Y12 inhibitor therapy, balancing ischemic and bleeding risks.
Limitations
- Recent prospective randomized trials evaluating personalized antiplatelet therapy based on platelet function testing did not demonstrate clinical benefit.
- Trials were limited by low event rates, suboptimal interventions, and inclusion of low-risk patients.
- Major limitations of randomized trials evaluating platelet function testing
- Low positive predictive value of platelet function testing
- Heterogeneous definitions of bleeding across trials
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The practice guidelines continue to either not provide strong recommendations or overall completely fail to acknowledge the topic, which, in my opinion, has sufficient evidence to support its use, not routinely in all patients but definitely in a number of patients.”
GBGeoff BarnesCardiologist, University of Michigan
“This document, to me, now provides a very state-of-the-art framework for when a clinician would consider either platelet function or genetic testing to help them make the best decision for an individual patient.”
DVDeepak VooraPharmacogenomics researcher, Duke University School of Medicine
“I think there's solid evidence out there, so let's focus on making it easy to do in clinical practice.”
Implication
Standardizes platelet function test thresholds for risk stratification post-PCI; leaves open whether routine testing and tailored.
Abstract
Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Tantry et al. (2013) conducted a review in Coronary artery disease. Platelet function testing was evaluated. Platelet function testing to define a therapeutic window of on-treatment platelet reactivity is proposed to balance the risks of post-percutaneous coronary intervention ischemic and bleeding events.
Topics
View Full Paper
Ask AI
Bookmark
Share